伴癫痫发作的抗N-甲基-D-天冬氨酸受体脑炎患者癫痫复发危险因素分析

doi:10.3969/j.issn.1672-6731.2025.11.009

中国现代神经疾病杂志 ›› 2025, Vol. 25 ›› Issue (11): 1034-1039. doi: 10.3969/j.issn.1672-6731.2025.11.009

• 癫痫相关疾病 • 上一篇

2 伴癫痫发作的抗N-甲基-D-天冬氨酸受体脑炎患者癫痫复发危险因素分析

王雪¹, 刘霄^1,2, 王群^1,2,3

1 100070 首都医科大学附属北京天坛医院神经病学中心;
2 100070 北京, 国家神经系统疾病临床医学研究中心;
3 450046 郑州大学第一附属医院神经内科

收稿日期:2024-12-12 发布日期:2025-12-05
通讯作者: 王群，Email：wangq@ccmu.edu.cn
基金资助:
国家重点研发计划“常见多发病防治研究”重点专项（项目编号：2022YFC2503800）；首都卫生发展科研专项（项目编号：首发2024-1-2041）；国家自然科学基金资助项目（项目编号：82371449）；北京市自然科学基金资助项目（项目编号：7232045）；北京市自然科学基金资助项目（项目编号：Z200024）

Risk factors for epilepsy recurrence in anti-N-methyl-D-aspartate receptor encephalitis patients with epileptic seizure

WANG Xue¹, LIU Xiao^1,2, WANG Qun^1,2,3

1 Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;
2 China National Clinical Research Center for Neurological Diseases, Beijing 100070, China;
3 Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450046, He'nan, China

Received:2024-12-12 Published:2025-12-05
Supported by:
This study was supported by National Key Research and Development Program of China "Common Disease Prevention and Control Research" Key Project (No. 2022YFC2503800), Capital Health Research and Development of Special Project (No. 2024-1-2041), the National Natural Science Foundation of China (No. 82371449), and Beijing Natural Science Foundation (No. 7232045, Z200024).

摘要/Abstract

摘要： 目的筛查伴癫痫发作的抗N-甲基-D-天冬氨酸受体（NMDAR）脑炎患者癫痫复发的危险因素。方法纳入2013年8月至2022年9月首都医科大学附属北京天坛医院收治的78例伴癫痫发作的抗NMDAR脑炎患者，根据随访期间是否癫痫复发分为癫痫复发组（18例）和癫痫未复发组（60例），单因素和多因素Logistic回归分析筛查伴癫痫发作的抗NMDAR脑炎患者癫痫复发的危险因素。结果共78例患者中18例（23.08%）随访期间［平均（2.21 ± 0.45）年］癫痫复发。多因素Logistic回归分析显示，合并肿瘤（OR=24.154，95% CI：2.597~224.640；P=0.005）、认知功能障碍（OR=7.809，95% CI：1.338~45.557；P=0.022）和头部MRI表现为皮质病变（OR=9.868，95% CI：1.223~79.620；P=0.032）是伴癫痫发作的抗NMDAR脑炎患者癫痫复发的危险因素。结论对于合并肿瘤、认知功能障碍和头部MRI表现为皮质病变的伴癫痫发作的抗NMDAR脑炎患者，应更长期应用抗癫痫发作药物，以避免癫痫复发。

关键词: 抗N-甲基-D-门冬氨酸受体脑炎, 癫痫, 复发, 预后, 危险因素, Logistic模型

Abstract: Objective To investigate the risk factors for epilepsy recurrence in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis patients with epileptic seizure. Methods A total of 78 anti-NMDAR encephalitis patients with epileptic seizure admitted to Beijing Tiantan Hospital, Capital Medical University from August 2013 to September 2022 were included. Clinical data of the patients were analyzed, and epilepsy recurrence was observed during follow-up period. According to whether epilepsy recurrence occurred during the follow-up period, the patients were divided into epilepsy recurrence group (n=18) and epilepsy non-recurrence group (n=60). Univariate and multivariate Logistic regression analyses were used to screen risk factors for epilepsy recurrence in anti-NMDAR encephalitis patients with epileptic seizure. Results During (2.21 ± 0.45) years' follow-up, 18 cases (23.08%) experienced epilepsy recurrence. Multivariate Logistic regression analysis showed that combined tumors (OR=24.154, 95%CI: 2.597-224.640; P=0.005), cognitive impairment (OR=7.809, 95%CI: 1.338-45.557; P=0.022), and cortical lesions on MRI (OR=9.868, 95%CI: 1.223-79.620; P=0.032) were risk factors for epilepsy recurrence in anti-NMDAR encephalitis patients with epileptic seizure. Conclusions Combined tumors, cognitive impairment, and cortical lesions on MRI are risk factors for epilepsy recurrence in anti-NMDAR encephalitis patients with epileptic seizure. For patients with these factors, longer duration of antiepileptic seizure medicine (ASM) should be used to avoid epilepsy recurrence.

Key words: Anti-N-methyl-D-aspartate receptor encephalitis, Epilepsy, Recurrence, Prognosis, Risk factors, Logistic models

王雪, 刘霄, 王群. 伴癫痫发作的抗N-甲基-D-天冬氨酸受体脑炎患者癫痫复发危险因素分析[J]. 中国现代神经疾病杂志, 2025, 25(11): 1034-1039.

WANG Xue, LIU Xiao, WANG Qun. Risk factors for epilepsy recurrence in anti-N-methyl-D-aspartate receptor encephalitis patients with epileptic seizure[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2025, 25(11): 1034-1039.

https://journal11.magtechjournal.com/cjcnn/CN/Y2025/V25/I11/1034

参考文献

[1] Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists:mechanisms and models[J]. Lancet Neurol, 2019, 18:1045-1057.
[2] Zhou K, Zhang L, Shen S, Lin JF, Wang JR, Zhou D, Li JM, Sima X. Neurological autoantibody prevalence in chronic epilepsy:clinical and neuropathologic findings[J]. Seizure, 2024, 115:28-35.
[3] Geis C, Planagumà J, Carreño M, Graus F, Dalmau J. Autoimmune seizures and epilepsy[J]. J Clin Invest, 2019, 129:926-940.
[4] Villéga F, Prüss H, van Elst LT, Groc L. Cognitive and psychiatric features of anti-NMDA receptor encephalitis[J]. Lancet Neurol, 2022, 21:861-862.
[5] Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, Zanette G, Zanoni T, Turatti M, Vitale G, Cadaldini M, Rossi F, Di Tizio L, Zuco C, Maniscalco GT, Soldani F, Monaco S, Trinka E, Hoeftberger R, Mariotto S. Epileptic seizures of suspected autoimmune origin:a multicentre retrospective study[J]. J Neurol Neurosurg Psychiatry, 2020, 91:1145-1153.
[6] Xu X, Lu Q, Huang Y, Fan S, Zhou L, Yuan J, Yang X, Ren H, Sun D, Dai Y, Zhu H, Jiang Y, Zhu Y, Peng B, Cui L, Guan H. Anti-NMDAR encephalitis:a single-center, longitudinal study in China[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 7:e633.
[7] Wang X, Wan J, Wei Z, Song C, Kang X, Du F, Jiang W, Yang F. Status epilepticus in patients with anti-NMDAR encephalitis requiring intensive care:a follow-up study[J]. Neurocrit Care, 2022, 36:192-201.
[8] de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, van Donselaar CA, Majoie MHJM, Neuteboom RF, Sillevis Smitt PAE, Thijs RD, Titulaer MJ. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis[J]. Neurology, 2019, 92:e2185-e2196.
[9] Yeshokumar AK, Coughlin A, Fastman J, Psaila K, Harmon M, Randell T, Schorr EM, Han H, Hoang H, Soudant C, Jette N. Seizures in autoimmune encephalitis:a systematic review and quantitative synthesis[J]. Epilepsia, 2021, 62:397-407.
[10] Steriade C, Britton J, Dale RC, Gadoth A, Irani SR, Linnoila J, McKeon A, Shao XQ, Venegas V, Bien CG. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy:conceptual definitions[J]. Epilepsia, 2020, 61:1341-1351.
[11] Zhang W, Wang X, Shao N, Ma R, Meng H. Seizure characteristics, treatment, and outcome in autoimmune synaptic encephalitis:a long-term study[J]. Epilepsy Behav, 2019, 94:198-203.
[12] Shen CH, Fang GL, Yang F, Cai MT, Zheng Y, Fang W, Guo Y, Zhang YX, Ding MP. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis[J]. Ann Clin Transl Neurol, 2020, 7:1392-1399.
[13] Liu X, Guo K, Lin J, Gong X, Li A, Zhou D, Hong Z. Long-term seizure outcomes in patients with autoimmune encephalitis:a prospective observational registry study update[J]. Epilepsia, 2022, 63:1812-1821.
[14] Chinese Society of Neuroinfectious Diseases and Cerebrospinal Fluid Cytology. Chinese expert consensus on the diagnosis and management of autoimmune encephalitis (2022 edition)[J]. Zhonghua Shen Jing Ke Za Zhi, 2022, 55:931-949.[中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组. 中国自身免疫性脑炎诊治专家共识(2022年版)[J]. 中华神经科杂志, 2022, 55:931-949.]
[15] Rada A, Hagemann A, Aaberg Poulsen C, Baumgartner T, Berki T, Blaabjerg M, Brenner J, Britton JW, Christiana A, Ciano-Petersen NL, Crijnen Y, Elišák M, Farina A, Friedman AR, Hayden Z, Hébert J, Holtkamp M, Hong Z, Honnorat J, Ilyas-Feldmann M, Irani SR, Kovac S, Marusic P, Muñiz-Castrillo S, Ramanathan S, Smith KM, Steriade C, Strippel C, Surges R, Titulaer MJ, Uy CE, de Vries JM, Bien CG, Specht U. Risk of seizure recurrence due to autoimmune encephalitis with NMDAR, LGI1, CASPR2, and GABABR antibodies:implications for return to driving[J]. Neurol Neuroimmunol Neuroinflamm, 2024, 11:e200225.
[16] Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, Gerner ST, Reimann G, Häusler M, Handreka R, Hellwig K, Kaufmann M, Kellinghaus C, Koertvelyessy P, Kraft A, Lewerenz J, Menge T, Paliantonis A, von Podewils F, Prüss H, Rauer S, Ringelstein M, Rostásy K, Schirotzek I, Schwabe J, Sokolowski P, Suesse M, Sühs KW, Surges R, Tauber SC, Thaler F, Bergh FT, Urbanek C, Wandinger KP, Wildemann B, Mues S, Zettl U, Leypoldt F, Melzer N, Geis C, Malter M, Kunze A; and the Generate Study Group. Seizure semiology in antibody-associated autoimmune encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2022, 9:e200034.
[17] Wesselingh R, Broadley J, Buzzard K, Tarlinton D, Seneviratne U, Kyndt C, Stankovich J, Sanfilippo P, Nesbitt C, D'Souza W, Macdonell R, Butzkueven H, O'Brien TJ, Monif M. Electroclinical biomarkers of autoimmune encephalitis[J]. Epilepsy Behav, 2022, 128:108571.
[18] Yao L, Yue W, Xunyi W, Jianhong W, Guoxing Z, Zhen H. Clinical features and long-term outcomes of seizures associated with autoimmune encephalitis:a follow-up study in East China[J]. J Clin Neurosci, 2019, 68:73-79.
[19] Chen B, Lopez Chiriboga AS, Sirven JI, Feyissa AM. Autoimmune encephalitis-related seizures and epilepsy:diagnostic and therapeutic approaches[J]. Mayo Clin Proc, 2021, 96:2029-2039.
[20] Huang F, Wu Y, Nong W, Mao F, Cao X, Huang W, Zheng J. Factors influencing the withdrawal of antiepileptic drugs in adult patients with symptomatic seizures secondary to neuronal surface antibodies-associated autoimmune encephalitis[J]. J Inflamm Res, 2022, 15:927-937.
[21] Nabizadeh F, Ramezannezhad E, Sardaripour A, Seyedi SA, Salehi N, Rezaeimanesh N, Naser Moghadasi A.[18F]FDG brain PET and clinical symptoms in different autoantibodies of autoimmune encephalitis:a systematic review[J]. Neurol Sci, 2022, 43:4701-4718.
[22] Zhao YY, Han B, Qin CH, Shi XX, Yun WJ, Wang M, Yuan B, Sun TW, Wang HX. Brain magnetic resonance imaging predictors in anti-N-methyl-D-aspartate receptor encephalitis[J]. Ann Clin Transl Neurol, 2022, 9:1974-1984.
[23] Wei YC, Tseng JR, Wu CL, Su FC, Weng WC, Hsu CC, Chang KH, Wu CF, Hsiao IT, Lin CP. Different FDG-PET metabolic patterns of anti-AMPAR and anti-NMDAR encephalitis:case report and literature review[J]. Brain Behav, 2020, 10:e01540.
[24] Horomanski A, Forbess LJ. The role of imaging in diagnosis and monitoring of large vessel vasculitis[J]. Rheum Dis Clin North Am, 2023, 49:489-504.

选择文件类型/文献管理软件名称

选择包含的内容

2 伴癫痫发作的抗N-甲基-D-天冬氨酸受体脑炎患者癫痫复发危险因素分析

Risk factors for epilepsy recurrence in anti-N-methyl-D-aspartate receptor encephalitis patients with epileptic seizure

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邱炳辉, 杜佳澍, 钟晴蕾, 卓杰, 何山. 应重视下丘脑垂体功能障碍对重型颅脑创伤患者长期预后的影响[J]. 中国现代神经疾病杂志, 2025, 25(9): 779-783.
[2]	夏金, 权柳燕, 包贇, 杜佳澍, 陈哲, 覃军. 颅脑创伤并脑出血患者控制性减压联合开颅血肿清除术疗效分析[J]. 中国现代神经疾病杂志, 2025, 25(9): 814-819.
[3]	邹敏刚, 周椿昊, 谢铖, 李卫, 蒋秋华, 黄乾亮. 颅脑异物贯通伤救治策略与预后分析[J]. 中国现代神经疾病杂志, 2025, 25(9): 820-827.
[4]	张杰华, 王旎, 朱栋梁, 高杰, 吴楚伟, 黄贤键. 创伤早期血清磷变异系数对中至重型颅脑创伤患者近期预后的预测[J]. 中国现代神经疾病杂志, 2025, 25(9): 828-833.
[5]	吕华东, 蓝瑞芳, 陈强棠, 劳小芳. 急性大动脉闭塞性缺血性卒中Solitaire支架多模式血管内治疗后首次再通影响因素分析[J]. 中国现代神经疾病杂志, 2025, 25(9): 854-861.
[6]	张辰雨, 张韶鹏, 李沛泉, 白云鹏, 陈彤云, 陈庆良. 急性A型主动脉夹层患者孙氏手术后新发缺血性卒中危险因素分析[J]. 中国现代神经疾病杂志, 2025, 25(8): 739-747.
[7]	杨潇, 刘松, 国晶晶, 田超, 韩彤, 靳松. 机器学习模型在急性前循环大血管闭塞性缺血性卒中机械取栓术后预后预测中的应用[J]. 中国现代神经疾病杂志, 2025, 25(8): 761-770.
[8]	张治中, 攸娜, 刘明航, 李泽, 孙国臣, 赵恺. MRI特征对胶质瘤MGMT启动子甲基化状态的预测作用[J]. 中国现代神经疾病杂志, 2025, 25(7): 595-601.
[9]	王逸捷, 胡瑞萍, 周裕瑶, 路俊锋. 左侧中央前回中部和额中回后部胶质瘤术后功能预后分析[J]. 中国现代神经疾病杂志, 2025, 25(7): 608-615.
[10]	张磊, 屈同钧, 吴盛, 张涛, 张国斌. 自发性颅内出血术后急性肾损伤影响因素分析[J]. 中国现代神经疾病杂志, 2025, 25(7): 650-660.
[11]	丁宏岩, 谢亚男, 董强. 脑静脉血栓形成患者颅内压增高影响因素分析[J]. 中国现代神经疾病杂志, 2025, 25(6): 483-488.
[12]	张静, 葛晗明, 韩楠楠, 张乐石, 刘志勤, 常明则. 重症脑静脉窦血栓形成抽吸取栓联合静脉窦置管溶栓疗效分析[J]. 中国现代神经疾病杂志, 2025, 25(6): 489-495.
[13]	聂放, 蔡恒, 唐伟, 李进伟, 付开磊, 李志清. 重症脑静脉窦血栓形成血管内治疗预后分析[J]. 中国现代神经疾病杂志, 2025, 25(6): 496-502.
[14]	丁乐, 石淼, 薛秀云, 张全增, 刘志勤. 贫血致复发性脑静脉血栓形成一例并文献复习[J]. 中国现代神经疾病杂志, 2025, 25(6): 530-537.
[15]	宋慧珍, 程忻, 苏娅. CT影像学标志物对脑叶出血预后的预测价值[J]. 中国现代神经疾病杂志, 2025, 25(5): 375-380.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 伴癫痫发作的抗N-甲基-D-天冬氨酸受体脑炎患者癫痫复发危险因素分析

Risk factors for epilepsy recurrence in anti-N-methyl-D-aspartate receptor encephalitis patients with epileptic seizure

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价